Varex Imaging (VREX) Jefferies 2024 Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies 2024 Global Healthcare Conference summary
8 Jul, 2026Market overview and growth drivers
Medical segment grows 2%-4% annually, driven by population growth, aging, and new technologies.
Industrial segment represents 25% of sales, growing 6%-8% annually, with applications in oil & gas, food inspection, and automotive.
Customer relationships are highly sticky, with most OEMs remaining for decades.
Industrial growth is supported by greenfield X-ray applications and strong cargo inspection demand.
Current challenges and regional dynamics
Medical segment faces mid-teens revenue decline in H1, mainly due to China softness and global inventory adjustments.
China business is impacted by an anti-corruption campaign and represents 14% of H1 revenue.
Inventory destocking globally is expected to last 6-9 months, with gradual recovery anticipated.
Recovery in China is expected to be gradual, influenced by macro conditions and the pace of anti-corruption campaign resolution.
A government stimulus package in China is in early administrative stages, with positive impact expected in a few months.
Competitive landscape and innovation
Minimal competition in X-ray sources; some competition in static detectors from Asia-based firms, but limited revenue exposure.
Industry trend is toward more outsourcing, with increasing OEM specialization and demand for focused solutions.
Value proposition centers on scale, R&D focus, and ability to offer innovative products at attractive prices.
Latest events from Varex Imaging
- Q1 revenue up 5% to $200M, margin 35%, strong security orders, and Q2 growth outlook.VREX
Q1 20258 Jul 2026 - Annual guidance, India ramp, photon counting, and AI drive growth and strategic flexibility.VREX
Jefferies Global Healthcare Conference 20263 Jun 2026 - Q2 FY26 revenue rose 1–1.5% to $216M, with non-GAAP EPS at $0.21 and lower leverage from refinancing.VREX
Q2 20268 May 2026 - Stable demand, India expansion, and photon counting tech position for growth amid policy uncertainty.VREX
Sidoti March Small-Cap Virtual Conference18 Mar 2026 - Stable demand, India ramp-up, and photon counting drive growth and margin outlook.VREX
Oppenheimer 36th Annual Healthcare MedTech & Services Conference17 Mar 2026 - All board nominees, executive pay, and auditor ratification were approved by stockholders.VREX
AGM 202612 Feb 2026 - Revenue up 5% to $210M, 90% EPS growth, strong industrial momentum, and positive Q2 outlook.VREX
Q1 202611 Feb 2026 - Revenue beat guidance, but a $93.9M goodwill impairment led to a GAAP net loss.VREX
Q3 20253 Feb 2026 - Photon counting tech, China recovery, and debt reduction drive 2025 outlook amid trade risks.VREX
Small-Cap Growth Virtual Investor Conference3 Feb 2026